

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

Claims 1-68. (Canceled)

69. (New) A composition comprising one or more antibodies that binds soluble aggregated amyloid  $\beta$  protein.

70. (New) A composition comprising one or more antibodies that binds soluble, non-fibrillar aggregated amyloid  $\beta$  protein.

71. (New) A composition comprising one or more antibodies that interacts preferentially with soluble, non-fibrillar oligomeric assemblies of amyloid  $\beta$  protein.

72. (New) The composition of claim 69, wherein the aggregated amyloid  $\beta$  proteins are full length amyloid  $\beta$ .

73. (New) A composition as in claim 71, wherein the assemblies are ADDLs.

74. (New) A composition comprising one or more antibodies that binds soluble aggregated amyloid  $\beta_{1-42}$ .

75. (New) The composition of claim 74 wherein the aggregated soluble amyloid  $\beta_{1-42}$  is identified as AN1792.

76. (New) A composition comprising one or more antibodies that binds soluble non-fibrillar aggregated amyloid  $\beta_{1-42}$ .

77. (New) The composition of claim 76 wherein the soluble non-fibrillar aggregated amyloid  $\beta_{1-42}$  is identified as AN1792.

78. (New) A composition comprising one or more antibodies that specifically binds soluble aggregated amyloid  $\beta_{1-42}$ .

79. (New) The composition of claim 78 wherein the aggregated soluble amyloid  $\beta_{1-42}$  is identified as AN1792.

80. (New) A composition comprising one or more antibodies that specifically binds soluble non-fibrillar aggregated amyloid  $\beta_{1-42}$ .

81. (New) The composition of claim 76 wherein the soluble non-fibrillar aggregated amyloid  $\beta_{1-42}$  is identified as AN1792.

82. (New) A composition comprising one or more antibodies that bind preferentially to soluble, globular, non-fibrillar protein assemblies of amyloid  $\beta_{1-42}$ .

83. (New) A composition as in claim 74, wherein the assemblies are ADDLs.

84. (New) A composition as in claim 82, wherein the assemblies are ADDLs.

85. (New) A composition comprising antibodies that binds soluble aggregated amyloid  $\beta$  protein.

86. (New) The composition of claim 85 wherein the aggregated soluble amyloid  $\beta_{1-42}$  is identified as AN1792.

87. (New) A composition comprising antibodies that binds soluble non-fibrillar aggregated amyloid  $\beta$  protein.

88. (New) The composition of claim 87 wherein the soluble non-fibrillar aggregated amyloid  $\beta$  protein is AN1792.

89. (New) A composition comprising antibodies that specifically binds soluble aggregated amyloid  $\beta$  protein.

90. (New) The composition of claim 89 wherein the aggregated soluble amyloid  $\beta_{1-42}$  is identified as AN1792.

91. (New) A composition comprising antibodies that specifically binds soluble non-fibrillar aggregated amyloid  $\beta$  protein.

92. (New) The composition of claim 91 wherein the soluble non-fibrillar aggregated amyloid  $\beta$  protein is AN1792.

93. (New) A composition comprising antibodies that bind preferentially to amyloid  $\beta$  -derived diffusible ligands (ADDLs).

94. (New) A composition comprising one or more antibody binding sites that specifically binds soluble amyloid  $\beta$  protein.

95. (New) A composition comprising one or more antibody binding sites that bind preferentially to ADDLs.

96. (New) A composition comprising one or more modified antibody binding sites that bind soluble aggregated amyloid  $\beta$  protein.

97. (New) A composition comprising one or more antibody binding sites that bind soluble amyloid  $\beta$  protein, wherein said antibody sites are derived from genetically engineered antibodies or fragments thereof.

98. (New) A composition comprising one or more modified antibody binding sites that specifically bind soluble aggregated amyloid  $\beta$  protein.

99. (New) A composition comprising one or more antibody binding sites that specifically bind soluble amyloid  $\beta$  protein, wherein said antibody sites are derived from genetically engineered antibodies or fragments thereof.

100. (New) A composition comprising one or more modified antibody binding sites that bind preferentially to ADDLs.

101. (New) A composition consisting of one or more binding sites that specifically bind soluble amyloid  $\beta$  protein, wherein said antibody sites are derived from genetically engineered antibodies or fragments thereof.

102. (New) A composition consisting of one or more binding sites that preferentially bind to ADDLs.

103. (New) The composition of any of claims 69, 70, 72, 74-77, 83, 85-88, 96, or 97, wherein the aggregated amyloid  $\beta$  protein binding site is incorporated into a human antibody framework.

104. (New) The composition of any of claims 78-81, 89-92, 94, 98, 99 or 101, wherein the aggregated amyloid  $\beta$  protein binding site is incorporated into a human antibody framework.

105. (New) Any composition of any of claims 71, 73, 82, 84, 93, 95, 100 or 102, wherein the ADDL binding site is incorporated into a human antibody framework.

106. (New) A method for detecting, in a tissue sample taken from a patient, the presence of soluble aggregated amyloid  $\beta$  protein, the method comprising contacting the sample with the composition of any of claims 69-70, 72, 74-81, 83, 85-92, 94, 96-99, 101, 103, 104, 106 or 107.

107. (New) A method for detecting, in a tissue sample taken from a patient, the presence of soluble non-fibrillar aggregated amyloid  $\beta$  protein, the method comprising contacting the sample with the composition of any of claims 69-70, 72, 74-81, 83, 85-92, 94, 96-99, 101, 103, 104, 106 or 107.

108. (New) A method for detecting, in fluid taken from a patient, the presence of soluble, non-fibrillar assemblies of amyloid  $\beta$  protein, the method comprising contacting the fluid with the composition as in any one of claims 71, 73, 82, 84, 93, 95, 100, 102, 105 or 108 and determining the presence of the assemblies.

109. (New) A method for reducing or terminating the progression of amyloidogenic disease in a patient, comprising administering an effective dosage of the composition of any one of claims 69-70, 72, 74-81, 83, 85-92, 94, 96-99, 101, 103, 104, 106, or 107 to the patient.

110. (New) A method for counteracting the effects of soluble, non-fibrillar assemblies of amyloid  $\beta$  protein, the method comprising administering the composition as in any one of claims 71, 73, 82, 84, 93, 95, 100, 102, 105, or 108 to a patient in need of such treatment.